- Home
- JAGU vs PRPO Comparison
JAGU vs PRPO Comparison
Compare JAGU & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAGU | PRPO |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Canada | United States |
| Employees | 3 | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2M | 40.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | JAGU | PRPO |
|---|---|---|
| Price | $1.61 | $23.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 130.0K | 18.5K |
| Earning Date | 03-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $1.44 | $10.60 |
| 52 Week High | $3.60 | $33.63 |
Technical Indicators
Market Signals| Indicator | JAGU | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 43.02 |
| Support Level | $1.58 | $21.71 |
| Resistance Level | $2.27 | $25.27 |
| Average True Range (ATR) | 0.20 | 1.22 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 33.54 | 48.61 |
Price Performance
Historical ComparisonAbout JAGU Jaguar Uranium Corp. Class A Common Shares
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.